Trial reportOphthalmology2024
An Updated Simplified Severity Scale for Age-Related Macular Degeneration Incorporating Reticular Pseudodrusen: Age-Related Eye Disease Study Report Number 42.
Trial report in Ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 24 citations in OpenAlex.
- Cuticular Drusen and the Risk of Progression to Late Age-Related Macular Degeneration: A MACUSTAR Study Report.Ophthalmology science · 2026Article
- Bidirectional Retro mode differential imaging improves drusen boundary depiction in early and intermediate AMD: a pilot study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Non neovascular Age - related macular degeneration - Review on clinical and imaging advances.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Reticular pseudodrusen load is associated with an increased risk of stroke.BMJ open ophthalmology · 2026Article
- Drusen volume and reticular pseudodrusen volume from optical coherence tomography with deep learning as risk factors for progression to late age-related macular degeneration in eyes with reticular pseudodrusen and contralateral macular neovascularisation.The British journal of ophthalmology · 2026Article
- Clinically Explainable Disease Diagnosis Based on Biomarker Activation Map.IEEE transactions on bio-medical engineering · 2026Article
- OCT Risk Factors for Progression to Late-Stage Age-Related Macular Degeneration in the Amish Eye Study.Ophthalmology. Retina · 2026Observational
- Design and Baseline Characteristics of the Korean Age-Related Maculopathy Study (KARMS): A Nationwide Multicenter Prospective Observational Study.Ophthalmology science · 2026Article
- A Simplified Classification for Age-Related Macular Degeneration Based on Optical Coherence Tomography.medRxiv : the preprint server for health sciences · 2026Article
- Minimum set of outcome measures for non-advanced age-related macular degeneration: a Delphi consensus statement by the TRACER (intermediate age-related macular degeneration) study group.The British journal of ophthalmology · 2026Article
- ReticularNet: Automated Pixel-Level Segmentation of Reticular Pseudodrusen on Near-Infrared Reflectance Images by Deep Learning.Ophthalmology science · 2026Article
- Prognostic Ability of Automated RPE Sinuosity for Late AMD Supersedes Qualitative Outer Retinal Band Assessment.Investigative ophthalmology & visual science · 2026Article
- Diagnostic Performance of Ring Aperture Retro Mode Imaging for Detecting Pigment Migration in Age-Related Macular Degeneration.Diagnostics (Basel, Switzerland) · 2025Article
- Proposal of a Simpler Eye-Level Risk Model Incorporating Reticular Pseudodrusen for the Clinical Prediction of Late Age-Related Macular Degeneration.Clinical & experimental ophthalmology · 2025Article
- Influence of subretinal drusenoid deposit on retinal sensitivity in age-related macular degeneration.Scientific reports · 2025Article
- Total Retinal Pigment Epithelium Thickness and Reflectivity, in Relation to Histology and Vision, at the Aging-AMD Transition: ALSTAR2 Baseline.Investigative ophthalmology & visual science · 2025Article
- High risk does not guarantee high accuracy-Evaluating the prognostic accuracy of OCT biomarkers for predicting late AMD.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
- Towards Accountable AI in Eye Disease Diagnosis: Workflow, External Validation, and Development.ArXiv · 2025Article
- AI Workflow, External Validation, and Development in Eye Disease Diagnosis.JAMA network open · 2025Article
- Retinal Autophagy for Sustaining Retinal Integrity as a Proof of Concept for Age-Related Macular Degeneration.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo update the Age-Related Eye Disease Study (AREDS) simplified severity scale for risk of late age-related macular degeneration (AMD), including incorporation of reticular pseudodrusen (RPD), and to perform external validation on the Age-Related Eye Disease Study 2 (AREDS2).
designPost hoc analysis of 2 clinical trial cohorts: AREDS and AREDS2.
participantsParticipants with no late AMD in either eye at baseline in AREDS (n = 2719) and AREDS2 (n = 1472).
methodsFive-year rates of progression to late AMD were calculated according to levels 0 to 4 on the simplified severity scale after 2 updates: (1) noncentral geographic atrophy (GA) considered part of the outcome, rather than a risk feature, and (2) scale separation according to RPD status (determined by validated deep learning grading of color fundus photographs).
main outcome measuresFive-year rate of progression to late AMD (defined as neovascular AMD or any GA).
resultsIn the AREDS, after the first scale update, the 5-year rates of progression to late AMD for levels 0 to 4 were 0.3%, 4.5%, 12.9%, 32.2%, and 55.6%, respectively. As the final simplified severity scale, the 5-year progression rates for levels 0 to 4 were 0.3%, 4.3%, 11.6%, 26.7%, and 50.0%, respectively, for participants without RPD at baseline and 2.8%, 8.0%, 29.0%, 58.7%, and 72.2%, respectively, for participants with RPD at baseline. In external validation on the AREDS2, for levels 2 to 4, the progression rates were similar: 15.0%, 27.7%, and 45.7% (RPD absent) and 26.2%, 46.0%, and 73.0% (RPD present), respectively.
conclusionsThe AREDS AMD simplified severity scale has been modernized with 2 important updates. The new scale for individuals without RPD has 5-year progression rates of approximately 0.5%, 4%, 12%, 25%, and 50%, such that the rates on the original scale remain accurate. The new scale for individuals with RPD has 5-year progression rates of approximately 3%, 8%, 30%, 60%, and 70%, that is, approximately double for most levels. This scale fits updated definitions of late AMD, has increased prognostic accuracy, seems generalizable to similar populations, but remains simple for broad risk categorization. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.